SynthesisMalaria journal2021
Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis.
Synthesis in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Immune modulation and treatment outcomes among patients with malaria and typhoid fever in Yaoundé, Cameroon: a comparative analysis of inflammatory responses.BMJ public health · 2026Article
- Computational screening of natural inhibitors against Plasmodium falciparum kinases: Toward novel antimalarial therapies.PloS one · 2026Article
- Trends of malaria incidence, prevalence, mortality, and disability-adjusted life years in Eastern Africa region from 1990 to 2021: a systematic analysis from Global Burden of Disease 2021 study.Malaria journal · 2025Article
- Green synthesis of PEGylated iron oxide nanoparticles of Eriobotrya japonica leaves extract in combination with B3, against Plasmodium falciparum 3D7 strain.Tropical medicine and health · 2025Article
- Solidified reverse micellar solution-based chitosan-coated solid lipid nanoparticles as a new approach to enhance oral delivery of artemether in malaria treatment.BMC chemistry · 2025Article
- Effects of vector control interventions on spatio-temporal changes ofFrontiers in public health · 2025Article
- Kidney Toxicity Studies in Mice (BALB/C) Recurrently Infected withArchives of Razi Institute · 2024Article
- Prevalence, trends and associated factors of malaria in the Shai-Osudoku District Hospital, Ghana.Malaria journal · 2023Article
- African Centers of Excellence in Bioinformatics and Data Intensive Science: Building Capacity for Enhancing Data Intensive Infectious Diseases Research in Africa.Journal of infectious diseases & microbiology · 2023Article
- Request for Antimalarial Medicines and Their Dispensing Without a Prescription in Community Pharmacies in Rwanda.Integrated pharmacy research & practice · 2023Article
- Rapid and Specific Action of Methylene Blue againstPharmaceutics · 2022Article
- The West Africa ICEMR Partnerships for Guiding Policy to Improve the Malaria Prevention and Control.The American journal of tropical medicine and hygiene · 2022Article
- Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers.Annals of medicine and surgery (2012) · 2022Article
- Trends and predictive factors for treatment failure following artemisinin-based combination therapy among children with uncomplicated malaria in Ghana: 2005-2018.BMC infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundArtemisinin-based combination therapy (ACT) was deployed in 2005 as an alternative to chloroquine and is considered the most efficacious treatment currently available for uncomplicated falciparum malaria. While widespread artemisinin resistance has not been reported to date in Africa, recent studies have reported partial resistance in Rwanda. The purpose of this study is to provide a current systematic review and meta-analysis on ACT at Mali study sites, where falciparum malaria is highly endemic.
methodsA systematic review of the literature maintained in the bibliographic databases accessible through the PubMed, ScienceDirect and Web of Science search engines was performed to identify research studies on ACT occurring at Mali study sites. Selected studies included trials occurring at Mali study sites with reported polymerase chain reaction (PCR)-corrected adequate clinical and parasite response rates (ACPRcs) at 28 days. Data were stratified by treatment arm (artemether-lumefantrine (AL), the first-line treatment for falciparum malaria in Mali and non-AL arms) and analysed using random-effects, meta-analysis approaches.
resultsA total of 11 studies met the inclusion criteria, and a risk of bias assessment carried out by two independent reviewers determined low risk of bias among all assessed criteria. The ACPRc for the first-line AL at Mali sites was 99.0% (95% CI (98.3%, 99.8%)), while the ACPRc among non-AL treatment arms was 98.9% (95% CI (98.3%, 99.5%)). The difference in ACPRcs between non-AL treatment arms and AL treatment arms was not statistically significant (p = .752), suggesting that there are potential treatment alternatives beyond the first-line of AL in Mali.
conclusionsACT remains highly efficacious in treating uncomplicated falciparum malaria in Mali. Country-specific meta-analyses on ACT are needed on an ongoing basis for monitoring and evaluating drug efficacy patterns to guide local malaria treatment policies, particularly in the wake of observed artemisinin resistance in Southeast Asia and partial resistance in Rwanda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.